Current Affairs - Science - Discussion

QDENGA is India’s first approved dengue vaccine and is also known as TAK-003. Developed by the Japanese pharmaceutical company Takeda, it is a live attenuated tetravalent vaccine designed to provide protection against the four dengue virus types: DENV-1, DENV-2, DENV-3, and DENV-4. India’s Central Drugs Standard Control Organisation (CDSCO) granted marketing authorisation for QDENGA in July 2026 for individuals aged 4 to 60 years. The vaccine received WHO prequalification in 2024 and is administered in two doses given three months apart. It is expected to enter India’s private market by mid-2027, subject to regulatory and commercial procedures.